Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Immunic and keeping the price target at $10.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Matthew Caufield has given his Buy rating due to a combination of factors related to Immunic’s lead candidate, vidofludimus calcium, which shows promise in treating multiple sclerosis. The recent ECTRIMS Congress highlighted its dual mechanism of action, providing both neuroprotection and relapse prevention, which positions it uniquely in the market.
The Phase 2 CALLIPER trial results demonstrated significant reductions in disability worsening among patients with progressive multiple sclerosis, supporting its potential to address unmet needs in disease progression. Additionally, the Phase 2 EMPhASIS trial in relapsing-remitting MS patients showed long-term safety and efficacy, with a high percentage of patients remaining free of confirmed disability worsening. These findings, along with the ongoing Phase 3 ENSURE trials, underpin the confidence in vidofludimus calcium’s ability to impact both relapsing and progressive forms of MS, justifying the Buy rating and a price target of $10.
According to TipRanks, Caufield is a 4-star analyst with an average return of 10.1% and a 47.80% success rate. Caufield covers the Healthcare sector, focusing on stocks such as Opus Genetics, Diamedica Therapeutics, and LENZ Therapeutics.